Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer (BCC-RAD-13)
The Effect of FOLFIRINOX and Stereotactic Body Radiation Therapy for Locally Advanced, Non-Resectable Pancreatic Cancer
Sponsor: James Graham Brown Cancer Center
Listed as NCT02128100, this PHASE2 trial focuses on Pancreatic Cancer Non-resectable and remains completed. Sponsored by James Graham Brown Cancer Center, it has been updated 9 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jan 2021 — Apr 2024 [monthly]
Recruiting PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2019 [monthly]
Recruiting PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jan 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- James Graham Brown Cancer Center
- University of Louisville
For direct contact, visit the study record on ClinicalTrials.gov .